Novel Therapies for Chronic Rhinosinusitis with Nasal Polyps

Complimentary

Released on 3/25/22
Expires on 3/25/23

Categories: , , , , , , , , , ,
Illustration of inflamed nasal sinuses indicating sinusitis.

Start Activity

Program Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common and potentially debilitating condition in adults, impacting 13 million people in the U.S. The prevalence is 2-4 times more common in middle-aged adult males than females. CRSwNP is an essential clinical entity diagnosed based upon subjective and objective evidence of chronic sinonasal inflammation. The CRSwNP is frequently associated with asthma and allergic rhinitis, but the cellular and molecular mechanisms that contribute to the clinical symptoms are not fully understood. Symptoms include anterior or posterior rhinorrhea, nasal congestion, hyposmia, and/or facial pressure or pain lasting for greater than 12 weeks in duration. Defects in the sinonasal epithelial cell barrier increased exposure to pathogenic and colonized bacteria, and dysregulation of the host immune system plays prominent role in disease pathogenesis.

Intended Audience

This endured webcast is designed to meet the educational needs of pulmonologists, rhinologists, allergists, immunologists, otolaryngologists, internal medicine physicians, pathologists, nurse practitioners, physician assistants, respiratory therapists, nurses, and other multi-disciplinary care team members treating chronic rhinosinusitis with nasal polyps (CRSwNP).

Commercial Supporter

This activity is supported by an educational grant from GlaxoSmithKline.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

  • Outline the pathophysiology of rhinosinusitis-associated nasal polyps and how to guide the selection of novel biologic therapy
  • Accurately diagnose patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who may be eligible for treatment with biological therapy
  • Evaluate emerging agents for CRSwNP based on their efficacy and safety data

Accredited Providers

The University of Cincinnati, Amedco, and Medical Media Holdings, Inc. have collaborated to design and execute this activity.

AMA PRA Category 1 CreditTM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Medical Media Holdings, Inc. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The University of Cincinnati designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Contact Hour(s)

Accreditation Statement

Amedco, a CME/CE company, and Medical Media Holding Inc. jointly sponsor this activity. Amedco is jointly accredited by the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medical Media Holding Inc, the medical education company, serves as a content and logistic provider for this activity.

Designation Statement

Amedco designates this webinar for a maximum of 1.50 ANCC contact hours for nurses.

Additional Credit Information

Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.50 hours.

Note to Physician Assistants
AAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.50 hours.

Conflicts of Interest Policy

It is the policy of the University of Cincinnati, Amedco, and Medical Media Holdings to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Learner Assurance Statement

The University of Cincinnati, Amedco, and Medical Media Holdings is committed to mitigating all conflicts of interest issues that could arise as a result of prospective faculty members’ relationships with ineligible companies. The program planners are committed to retaining only those speakers with financial interests that can be mitigated as they relate to the goals and educational integrity of the CME activity.

Planners and Managers Disclosures

Everyone in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Kamatham A. Naidu, PhD (Medical Media Holding Inc.), has no relevant financial relationships.
Brian Waggoner (Medical Media Holding Inc.) has no relevant financial relationships to disclose.
Susan P. Tyler, PhD (University of Cincinnati), has no relevant financial relationships to disclose.
Heather Muskopf (University of Cincinnati), has no relevant financial relationships to disclose.
Bruce C. Gebhardt, MD (University of Cincinnati), has no relevant financial relationships to disclose.
Robert V. Ellis, MD (University of Cincinnati), has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

It is the policy of the University of Cincinnati, Amedco, and Medical Media Holdings to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

The University of Cincinnati, Amedco, and Medical Media Holdings do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Faculty

John V Bosso, MD
Professor
Division of Rhinology
Department of Otorhinolaryngology, Head and Neck Surgery
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

The following faculty has reported relevant relationships with ineligible companies that have been mitigated:
John V Bosso, MD, discloses that he is on the advisory board for AstraZeneca, GlaxoSmithKline, Novartis, and Regeneron; clinical research study P.I. for Cumberland.

Michael E Wechsler, MD, MMSc
Director
The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

The following faculty has reported relevant relationships with ineligible companies that have been mitigated:
Michael E Wechsler, MD, MMSc, discloses that he is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Equillium, Genentech, Genzyme, GlaxoSmithKline, Incyte, Kinaset, Novartis, Pulmatrix, Regeneron, Restorbio, Sanofi, Sound Biologics, Teva.

Instructions

There are no fees for participating and receiving CME/CE credit for this endured webcast. During the period from March 25, 2022 through March 25, 2023, participants must read all the material and study the educational webcast.

This endured webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 75% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your  Dashboard or Transcript, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider:

For physician/non-physician accreditation (ACCME/AMA), contact the University of Cincinnati at uc-cloudcme@ucmail.uc.edu.

For nursing accreditation (ANCC), contact Amedco at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

The University of Cincinnati, Amedco, and Medical Media Holdings observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

Webcast

Time to Complete: 1.50 hours

Released: March 25, 2022

Expires: March 25, 2023

Maximum Credits:
1.50 / AMA PRA Category 1 CreditsTM
1.50 / ANCC Contact Hours

Related products